SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DAVID who wrote (21297)4/23/1999 8:54:00 PM
From: Mkilloran  Read Replies (1) of 23519
 
David...it was very clearly stated in the conf call in Jan that the
distribution rights to Muse was the only thing that Astra and Janssen had.

Alibra is a whole new deal.

Given the advances of Alibra over Muse it would be a good bet that Astra/Zeneca and Janssen would want to extend their marketing of Muse with Alibra.

The reduced expense to produce Alibra may afford larger markups than MUSE even if the cost to the end consumer is reduced.

The origional deals to assign sales rights for Muse to Janssen and Astra go back to 1996/97.

The most likely time for Astra/Zeneca and Janssen to negotiate a deal for the rights to sell Alibra is as they complete Phase III trials IMO.

USA and Japan are the only two major countries that Vivus has not sold any rights to sell MUSE todate. The USA/Japan partners would
want rights to both products now.

This was not an option back in 1996/1997 when only MUSE was close to
becoming approved by the FDA.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News